[HSGX] Histogenics Corporation

Overview

Type of security: Stock

Sector: Health Care

Industry: Industrial Specialties

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.74 Change: 0.03 (1.75%)
Ext. hours: Change: 0 (0%)

chart HSGX

Refresh chart

Strongest Trends Summary For HSGX

HSGX is in the medium-term down -80% in 1 year and down -98% in 1 year.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-58.38% ROE-70.19% ROI
Current Ratio7.2 Quick Ratio Long Term Debt/Equity Debt Ratio0.15
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities4.72 M Cash From Investing Activities-920 K Cash From Operating Activities-8.69 M Gross Profit
Net Profit-7.96 M Operating Profit-7.87 M Total Assets61.58 M Total Current Assets54.01 M
Total Current Liabilities7.5 M Total Debt1.74 M Total Liabilities10.36 M Total Revenue
Technical Data
High 52 week18.6 Low 52 week0.09 Last close0.29 Last change-19.44%
RSI Average true range0.14 Beta-0.19 Volume58.5 K
Simple moving average 20 days-73.9% Simple moving average 50 days-93.19% Simple moving average 200 days-95.4%
Performance Data
Performance Week-49.41% Performance Month-85.28% Performance Quart-97.7% Performance Half-97.17%
Performance Year-35.56% Performance Year-to-date228.05% Volatility daily8.92% Volatility weekly19.96%
Volatility monthly40.9% Volatility yearly141.67% Relative Volume158.19% Average Volume5.75 M
New High New Low

News

2020-03-30 00:03:00 | Edited Transcript of HSGX earnings conference call or presentation 27-Mar-20 12:30pm GMT

2019-11-21 07:00:00 | Entera Bio Establishes U.S. Headquarters and Announces Jonathan Lieber as Chief Financial Officer

2019-10-01 15:04:38 | Malvern gene therapy company completes reverse merger

2019-09-26 16:25:00 | Histogenics Corporation Announces Approval of Merger by Stockholders at Special Meeting

2019-09-12 09:15:00 | Histogenics Corporation Announces Adjournment of its Special Meeting to Thursday, September 26, 2019

2019-09-11 16:05:00 | Histogenics Corporation Announces Intent to Convene and Adjourn Its Special Meeting

2019-04-30 08:00:00 | How Will Histogenics Shareholders Fare in the Merger with Ocugen

2019-04-08 17:50:05 | Histogenics News: Why Did HSGX Stock Soar Today?

2019-04-08 12:48:36 | Ocular Biotechs Histogenics, Ocugen Announce Stock-For-Stock Merger

2019-04-08 09:58:34 | Histogenics to serve as shell for Pennsylvania biotech in reverse-merger

2019-04-08 09:33:26 | Malvern gene therapy developer to acquire publicly traded Boston company

2019-04-08 07:00:00 | Histogenics and Ocugen Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics

2019-03-25 05:44:18 | Edited Transcript of HSGX earnings conference call or presentation 9-Nov-17 1:30pm GMT

2019-02-20 08:00:00 | Biotech Bounce Just Getting Started

2019-02-12 08:00:00 | Jonathan Lieber Joins Danforth Advisors as Managing Director

2019-01-31 08:00:00 | Biotech Stocks on the Rise

2019-01-28 09:30:02 | Is Histogenics HSGX Outperforming Other Medical Stocks This Year?

2019-01-23 08:30:00 | Best Ways to Play Biotech Rally

2019-01-08 08:30:00 | The Next Big Biotech Breakout

2019-01-04 08:50:00 | 4 Healthcare Stocks To Watch On Friday 1/4/19

2018-12-21 16:05:00 | Histogenics and FDA Conclude Discussions Regarding NeoCart® Phase 3 Clinical Trial Data and Regulatory Pathway

2018-11-29 08:30:00 | Histogenics and FDA Continue to Discuss NeoCart® Phase 3 Clinical Trial Data and Potential Regulatory Pathway

2018-11-23 07:50:00 | New Research Coverage Highlights Intersections, PRGX Global, Ecology and Environment, Histogenics, SeaChange International, and TransAct Technologies — Consolidated Revenues, Company Growth, and Expectations for 2018

2018-11-12 06:10:52 | Cell therapy biotech Vericel eyes $2B knee repair market

2018-11-08 07:07:35 | Histogenics: 3Q Earnings Snapshot

2018-11-08 06:30:00 | Histogenics Corporation Announces Third Quarter 2018 Financial and Operating Results

2018-11-01 16:05:00 | Histogenics and FDA to Continue Discussions on NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway

2018-10-25 16:15:00 | Histogenics Corporation to Report Third Quarter 2018 Financial Results on November 8, 2018

2018-10-24 08:15:00 | What is Next for Histogenics, Pending FDA Meeting and Analysts Target Price

2018-10-15 08:00:00 | Today’s Research Reports on Stocks to Watch: Immune Design and Histogenics

2018-10-10 16:01:00 | Histogenics Corporation Announces Closing of Public Offering of Common Stock and Warrants

2018-10-05 08:10:00 | Histogenics Corporation Announces Pricing of Public Offering of Common Stock and Warrants

2018-10-04 16:01:00 | Histogenics Corporation Announces Proposed Public Offering of Common Stock and Warrants

2018-09-26 16:05:00 | Histogenics to Meet With FDA to Discuss NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway

2018-09-05 12:04:30 | Histogenics Slips Below $1 Threshold After Knee Cartilage Candidate Fails Late-Stage Study

2018-09-05 11:56:58 | Histogenics to seek FDA approval for cell therapy despite failed study

2018-09-05 05:00:00 | Histogenics Announces Top-Line Results From Phase 3 Clinical Trial of NeoCart® in Patients With Knee Cartilage Damage

2018-08-10 20:40:05 | Edited Transcript of HSGX earnings conference call or presentation 9-Aug-18 12:30pm GMT

2018-08-10 05:08:09 | Histogenics Sees Hammer Chart Pattern: Time to Buy?

2018-08-09 06:49:33 | Histogenics: 2Q Earnings Snapshot

2018-08-09 06:30:00 | Histogenics Corp. to Host Earnings Call

2018-08-09 06:30:00 | Histogenics Corporation Announces Second Quarter 2018 Financial and Operating Results

2018-07-31 08:00:00 | Histogenics Corporation Appoints E. Lynne Kelley, M.D., FACS As Chief Medical Officer

2018-07-26 08:30:00 | Histogenics Corporation to Report Second Quarter 2018 Financial Results on August 9, 2018

2018-07-25 16:15:00 | Histogenics Corporation to Present at Canaccord Genuity’s 38th Annual Growth Conference

2018-07-23 08:30:00 | Histogenics Chief Operating Officer, Stephen Kennedy Appointed to Advanced Regenerative Manufacturing Institute’s Technology Advisory Sub-Committee

2018-05-31 08:30:00 | Histogenics Corporation to Host Investor Day on June 19, 2018

2018-05-11 12:55:23 | Edited Transcript of HSGX earnings conference call or presentation 10-May-18 12:30pm GMT

2018-05-10 06:39:10 | Histogenics: 1Q Earnings Snapshot

2018-05-10 06:30:00 | Histogenics Corporation Announces First Quarter 2018 Financial and Operating Results